Jefferies Downgrades Regado Biosciences (RGDO) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Jefferies Downgrades Regado Biosciences (RGDO) to Hold
August 25, 2014 12:01 PM EDT
BMO Capital analyst Jim Birchenough reiterated an Underperform rating and $1 price target on Regado Biosciences (NASDAQ: RGDO) after the company announced the permanent termination of the enrollment in the REGULATE-PCI phase 3 trial for the company's lead program, REVOLIXYS Kit. The analyst called it the... More
August 25, 2014 9:13 AM EDT
Deutsche Bank downgraded Regado Biosciences (NASDAQ: RGDO) from Buy to Hold with a price target of $2.00 (from $14.00). Earlier Regado Biosciences announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program, Revolixys Kit. The decision was made based on a recommendation from the trial's Data and Safety Monitoring Board (DSMB) following their analysis of the data... More
